Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Ostin Technology Group Co., Ltd. designs, develops, and manufactures thin-film transistor liquid crystal display (TFT-LCD) modules and polarizers in China. The company offers TFT-LCD solutions for drive IC, TCON board, and power supply applications; back light systems and special modules; LC display modules, touch panel modules, and smart display terminals; and polarizers used in the TFT-LCD display modules. It offers display modules to markets, such as consumer electronics, including AIOs, monitors, laptop computers, and tablets; automotive displays, including dashboard, and navigation and multimedia systems; and outdoor LCD displays, which are used to display multimedia graphics, such as company advertisements, promotions, scoreboards, and traffic signs. The company sells its products directly to customers, as well as to customers' designated system integrators. Ostin Technology Group Co., Ltd. was founded in 2010 and is based in Nanjing, China with manufacturing facilities in China.

Ostin Technology Group Co., Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

20% OF OST-HER2 TREATED DOGS SURVIVED 2-YEAR VS. 1% IN CONTROL GROUP (P = 0.00995) OVER 15,000 DOGS PER YEAR DIAGNOSED WITH OSTEOSARCOMA COMPANY EXPECTS TO SUBMIT U.S. DEPARTMENT OF AGRICULTURE MEETING REQUEST TO GAIN ALIGNMENT ON REGULATORY PATH TOWARDS CONDITIONAL APPROVAL IN THE THIRD QUARTER OF 2026 OS THERAPIES REITERATES PLAN TO DISTRIBUTE OS ANIMAL HEALTH SHARES TO SHAREHOLDERS OS ANIMAL HEALTH PLANS CROWDFUNDING TO EXPAND SHAREHOLDER BASE TO MEET U.S. NATIONAL EXCHANGE INITIAL LISTING STANDARDS, WITH INDICATIONS OF INTEREST NOW BEING RECEIVED ROCKVILLE, MARYLAND--(NEWSFILE CORP. - JUNE 26, 2026) - OS ANIMAL HEALTH, INC. ("OS ANIMAL HEALTH" OR "THE COMPANY"), THE WHOLLY-OWNED ANIMAL HEALTH SUBSIDIARY OF OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THE PEER-REVIEWED PUBLICATION OF DATA FROM THE PHASE 2 CLINICAL TRIAL OF OST-HER2, TOGETHER WITH PALLIATIVE RADIATION THERAPY ("RT"), AIMED AT PREVENTING AMPUTATION IN FRONTLINE CANINE OSTEOSARCOMA.

OS ANIMAL HEALTH ANNOUNCES PEER-REVIEWED PUBLICATION OF CLINICAL TRIAL DATA FOR OST-HER2 PLUS PALLIATIVE RADIATION AS FRONTLINE TREATMENT IN CANINE OSTEOSARCOMA

75% 2.5-YEAR OVERALL SURVIVAL FOR OST-HER2 VS. 47% POOLED HISTORICAL CONTROL (P = 0.003), WITH NO NEW PATIENT DEATHS REPORTED SINCE THE 2-YEAR OVERALL SURVIVAL DATA (75% VS.

OS THERAPIES ACHIEVES STATISTICALLY SIGNIFICANT 2.5-YEAR OVERALL SURVIVAL IN PHASE 2B TRIAL OF OST-HER2 IN FULLY RESECTED PULMONARY METASTATIC OSTEOSARCOMA

THE COMPANY CONFIRMS THAT IT WILL RELEASE 2.5 YEAR OVERALL SURVIVAL DATA FROM PHASE 2B CLINICAL TRIAL OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENCE IN FULLY-RESECTED PULMONARY METASTATIC OSTEOSARCOMA DURING THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGISTS (ASCO) ANNUAL MEETING BEING HELD FROM MAY 28, 2026 TO JUNE 2, 2026. NEW YORK, NEW YORK AND ROCKVILLE, MARYLAND--(NEWSFILE CORP. - MAY 29, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THE PUBLICATION OF FOUR ARTICLES RELATED TO OST-HER2 AND/OR OSTEOSARCOMA IN DRUG DISCOVERY WORLD.

OS THERAPIES ANNOUNCES THE PUBLICATION OF FOUR ARTICLES ON OST-HER2 AND OSTEOSARCOMA IN DRUG DISCOVERY WORLD

$5.5 MILLION FINANCING THAT CLOSED ON APRIL 2, 2026 TOGETHER WITH $5.7 MILLION IN CAPITAL RAISED IN Q1-2026, EXPECTED TO PROVIDE COMPANY WITH CASH RUNWAY INTO 2027 $4.5 MILLION OF ACCRUED VAT REFUNDS AND R&D REFUNDABLE TAX CREDITS FROM UK SUBSIDIARY BEGIN MATURING, INCLUDING $1.9 MILLION VAT CASH REFUND EXPECTED IN JUNE 2026 SUCCESSFUL EMA AND AUSTRALIA TGA (ATGA) MEETINGS ALIGNED AROUND USE OF EXISTING BIOMARKER AND PENDING RELEASE OF 3-YEAR OVERALL SURVIVAL DATA TO SUPPORT CONDITIONAL MARKETING AUTHORISATIONS (CMAS) FOR OST-HER2 IN PREVENTION OR DELAY OF RECURRENCE IN FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA ("METASTATIC OSTEOSARCOMA") 2.5-YEAR OVERALL SURVIVAL DATA EXPECTED TO BE RELEASED DURING ASCO 2026 EMA AND ATGA HAVE ALIGNED ON KEY DESIGN ASPECTS OF CONFIRMATORY PHASE 3 METASTATIC OSTEOSARCOMA PROTOCOL REQUIRED TO HAVE COMMENCED PRIOR TO GRANT OF CMAS OR FDA BLA, INCLUDING ALIGNMENT ON 3-YEAR OVERALL SURVIVAL AS A PRIMARY CLINICAL EFFICACY ENDPOINT UPCOMING U.S. FDA TYPE C MEETING AND U.K. MHRA SAM MEETING TO ALIGN WITH EMA & ATGA PRIOR TO AUSTRALIA CLINICAL TRIAL NOTIFICATION SUBMISSION FOR PHASE 3, INCLUDING ALIGNMENT ON 3-YEAR OVERALL SURVIVAL AS A PRIMARY CLINICAL EFFICACY ENDPOINT. U.S. FDA ("FDA") PRE-BLA MEETING TO CONFIRM ALIGNMENT ON SURROGATE AND PRIMARY CLINICAL EFFICACY ENDPOINTS WITH EMA/ATGA, INCLUDING ALIGNMENT ON 3-YEAR OVERALL SURVIVAL AS A PRIMARY CLINICAL EFFICACY ENDPOINT, AND SEEK DECISIONS ON ROLLING REVIEW ACCEPTANCE AND RMAT DESIGNATION FOLLOWING THE EMA AND U.K. MHRA GRANTING ATMP DESIGNATION (EMA/MHRA RMAT EQUIVALENT) FOR OST-HER2 IN METASTATIC OSTEOSARCOMA OS ANIMAL HEALTH S-1 FILING FOR PROPOSED 'GO-PUBLIC' TRANSACTION AND RECEIPT OF SEC COMMENTS NEW YORK, NEW YORK AND ROCKVILLE, MARYLAND--(NEWSFILE CORP. - MAY 18, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, REPORTED FIRST QUARTER 2026 FINANCIAL RESULTS AND PRO

OS THERAPIES REPORTS FIRST QUARTER 2026 FINANCIALS AND PROVIDES BUSINESS UPDATE

APPOINTMENT STRENGTHENS MEDICAL, REGULATORY, AND COMMERCIAL LEADERSHIP AS COMPANY PREPARES TO COMPLETE EARLY MARKET ACCESS REGULATORY FILINGS IN THE U.S., U.K, EUROPE AND AUSTRALIA IN ANTICIPATION OF OST-HER2 APPROVAL DECISIONS EXPECTED BY YEAR-END 2026 UPCOMING FDA PRE-BLA MEETING WILL FOCUS ON THE USE OF RECENT SEROCONVERSION BIOMARKER DATA AS A KEY SURROGATE CLINICAL EFFICACY ENDPOINT TO SUPPORT A BLA FOR OST-HER2 UNDER THE ACCELERATED APPROVAL PROGRAM COMMERCIALIZATION AND REIMBURSEMENT PREPARATIONS WELL UNDERWAY FOR THE U.S., U.K., AND EUROPE IN PARALLEL WITH ONGOING PARTNERSHIP DISCUSSIONS NEW YORK, NEW YORK AND ROCKVILLE, MARYLAND--(NEWSFILE CORP. - MAY 14, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, ANNOUNCED DR. CRAIG EAGLE'S APPOINTMENT AS CHIEF MEDICAL ADVISOR. HIS APPOINTMENT STRENGTHENS THE COMPANY'S MEDICAL, REGULATORY, AND COMMERCIAL LEADERSHIP TEAM IN PREPARATION FOR POTENTIAL EARLY MARKET ACCESS DECISIONS FROM REGULATORS AT THE U.S. FOOD & DRUG ADMINISTRATION (FDA), U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA), EUROPEAN MEDICINES AGENCY (EMA) AND AUSTRALIAN THERAPEUTIC GOOD ADMINISTRATIONS (ATGA) FOR OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENCE IN FULLY-RESECTED, PULMONARY METASTATIC OSTEOSARCOMA (THE "METASTATIC OSTEOSARCOMA PROGRAM").

OS THERAPIES APPOINTS INDUSTRY LEADER DR. CRAIG EAGLE AS CHIEF MEDICAL ADVISOR

30/04/2026 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE UNLAWFUL. CLARIANE SE POST-STABILISATION PERIOD ANNOUNCEMENT NO STABILISATION CARRIED OUT [FURTHER TO THE PRE-STABILISATION PERIOD ANNOUNCEMENT DATED 28/04/2026] BNP PARIBAS (CONTACT: STANFORD HARTMAN TELEPHONE: 0207 595 8222) HEREBY GIVES NOTICE THAT NO STABILISATION (WITHIN THE MEANING OF ARTICLE 3.2(D) OF THE MARKET ABUSE REGULATION (EU/596/2014)) WAS UNDERTAKEN BY THE STABILISATION MANAGER(S) NAMED BELOW IN RELATION TO THE OFFER OF THE FOLLOWING SECURITIES.

BNP PARIBAS PRIMARY NEW ISSUES:POST STAB NOTICE - NO STAB - CLARIANETAP

30/04/2026 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE UNLAWFUL. BEFIMMO POST-STABILISATION PERIOD ANNOUNCEMENT NO STABILISATION CARRIED OUT [FURTHER TO THE PRE-STABILISATION PERIOD ANNOUNCEMENT DATED 28/04/2026] BNP PARIBAS (CONTACT: STANFORD HARTMAN TELEPHONE: 0207 595 8222) HEREBY GIVES NOTICE THAT NO STABILISATION (WITHIN THE MEANING OF ARTICLE 3.2(D) OF THE MARKET ABUSE REGULATION (EU/596/2014)) WAS UNDERTAKEN BY THE STABILISATION MANAGER(S) NAMED BELOW IN RELATION TO THE OFFER OF THE FOLLOWING SECURITIES.

BNP PARIBAS PRIMARY NEW ISSUES:POST STAB NOTICE - NO STAB - BEFIMOO

CONFERENCE CALL SCHEDULED FOR THURSDAY, APRIL 30, 2026, AT 8:30 AM ET TO REVIEW NEW OST-HER2 IMMUNE PHARMACODYNAMIC BIOMARKER RESPONSE (SEROCONVERSION) DATA AND REVIEW REGULATORY SUCCESSES VALIDATING THE OST-HER2 APPROACH. PARTICIPANTS WILL INCLUDE STRATEGIC ADVISORS DR. CRAIG EAGLE AND DR. BOB LANGER, AND OSTEOSARCOMA KEY OPINION LEADER DR. PETER ANDERSON FROM CLEVELAND CLINIC.

OS THERAPIES ANNOUNCES EMA INITIATES ROLLING REVIEW OF CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR OST-HER2 IN THE PREVENTION OR DELAY OF RECURRENCE IN FULLY RESECTED PULMONARY METASTATIC OSTEOSARCOMA

REGULATORY FEEDBACK RECENT FROM APRIL 2026 EU EMA AND AUSTRALIAN TGA MEETINGS REMAINING Q2-2026 REGULATORY MEETINGS INCLUDE TWO U.S. FDA MEETINGS AND ONE UK MHRA MEETING, IN ADDITION TO FOLLOW-UP MEETINGS WITH EU EMA AND AUSTRALIAN TGA NEW YORK, NEW YORK--(NEWSFILE CORP. - APRIL 27, 2026) - OS THERAPIES, INC. (NYSE AMERICAN: OSTX) ("OS THERAPIES" OR "THE COMPANY"), THE WORLD LEADER IN GENE-EDITED, LISTERIA-BASED CANCER IMMUNOTHERAPIES, TODAY ANNOUNCED THAT IT WILL BE HOSTING A CONFERENCE CALL ON THURSDAY APRIL 30, 2026 AT 8:30AM ET TO REVIEW THE DATA THAT SUPPORTED THE RECENT PATENT COOPERATION TREATY (PCT) INTERNATIONAL APPLICATION FOR A OST-HER2 PHARMACODYNAMIC BIOMARKER 1(THE "OST-HER2 IMMUNE SIGNATURE") AS A SURROGATE CLINICAL EFFICACY ENDPOINT. THE OST-HER2 IMMUNE SIGNATURE IS EXPECTED TO BE USED TO SUPPORT EARLY MARKET ACCESS IN THE SECOND HALF OF 2026 IN THE U.S VIA A BIOLOGICS LICENSE APPLICATION ("BLA") UNDER THE ACCELERATED APPROVAL PROGRAM 2(ACCELERATED APPROVAL), IN ADDITION TO EUROPE, THE UK AND AUSTRALIA VIA CONDITIONAL MARKETING AUTHORISATIONS 3(CMAS).

OS THERAPIES SCHEDULES OST-HER2 PHARMACODYNAMIC RESPONSE BIOMARKER CONFERENCE CALL ON APRIL 30, 2026 AT 8:30AM ET

BRAGAR EAGEL & SQUIRE, P.C. LITIGATION PARTNER BRANDON WALKER ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN OSTIN (OST) TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

OSTIN DEADLINE TODAY: BRAGAR EAGEL & SQUIRE, P.C. URGES OSTIN TECHNOLOGY GROUP INVESTORS TO CONTACT THE FIRM BEFORE THE APRIL 17TH LEAD PLAINTIFF DEADLINE

Ostin Technology Group Co., Ltd.

OST

Price

Financial Reports

No items found.

Press Releases

Ostin Technology Group Co., Ltd.

OST.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OST